

The Utility of HLA-DR Genotyping As a Complementary Tool to Discriminate Undifferentiated and Rheumatoid Arthritis Patients in Early Arthritis.

Fernando Dal Pra¹, Gustavo Citera², Margarita Landis,
Christian A. Waimann⁴, Luis Alejandro Cayetti², Sergio Pairas, Federico
Ceccatto⁶, Teresita Alvarellos⁷, Luciana Mas⁷, Josefina Marcos⁸, Mercedes
García⁸, A Salas, Alejandro Martínez⁹, Rafael Chaparro¹⁰, Oscar Luis
Rillo⁹, Edson Veloso¹¹, Ricardo V. Juárez¹², María Elena Crespo¹³, Antonio
Catalán Pellet¹⁴, Anastasia Secco¹⁴, Lucila Marino¹⁴ and V Martire¹⁴.
¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Instituto de
Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto Rehabilitación
Psicofísica, Buenos Aires, Argentina, ⁴Hospital Olavarría, Olavarría, Argentina,
⁵Hospital Jose María Cullen, Santa Fe, Argentina, ⁶Hospital Jose María
Cullen, Santa Fe, Argentina, ⁷Hospital Privado Centro Médico De Córdoba,
Córdoba, Argentina, ⁸HIGA San Martín, La Plata, Argentina, ⁹Hospital
General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁰Hospital Gral.
de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹¹Sanatorio y Universidad
Adventista Del Plata, Entre Ríos, Argentina, ¹²Hospital Señor del Milagro,
Salta, Argentina, ¹³Hospital Señor Del Milagro, Salta, Argentina, ¹⁴Hospital
Bernardino Rivadavia, Buenos Aires, Argentina.

Background/Purpose: Only half of patients with undifferentiated arthritis (UA) will progress to rheumatoid arthritis (RA) after two years of follow-up. Particular human leukocyte antigens class II-DR (HLA-DR) alleles have been associated with a higher risk to develop RA, however these alleles may vary among ethnic groups. The aim of our study was to investigate the frequency of HLA-DR alleles and evaluate the association with the development of rheumatoid arthritis in an early arthritis cohort in Latin America.

Methods: We designed a case-control study. Cases were defined as patients with diagnosis of RA from an early arthritis cohort (<2 years of disease duration). Two control groups were selected. First group was obtained from the mentioned cohort and included patients with UA. The second control group was obtained from the national register of cadaveric organ donors (Healthy Subjects, HS). HLA-DR genotypes frequencies were estimated for each group. We calculated the odds ratio (OR) to develop RA in general population and undifferentiated arthritis. Statistical analysis was performed with two-tailed Pearson's chi-squared test with Bonferroni adjustment (p-value after Bonferroni adjustment, P_c). A stepwise logistic regression model using RA vs UA diagnosis as dependent variable was performed to identify the association of HLA-DR alleles and RA development in patients with UA, adjusted by smoking, gender and presence of rheumatoid factor (variable significance entry criteria P < 0.15). A p-value less than 0.05 was considered statistically significant.

Results: We included a total of 1859 subjects: AR₃₄₇; UA₅₂; Cs₁₄₆₀. When comparing with HS, RA patients had an increased frequency of DR4 [RA_{50%} vs HS_{31%}, OR 2.3 (1.7 – 2.8), P_c0.0001], DR9 [RA_{12%} vs HS_{7%}, OR 1.9 (1.3 – 2.8), P_c0.02], and lower frequency of DR7 [RA_{13%} vs 21%, OR 0.6 (0.4 – 0.8), P_c0.02], DR11 [RA_{10%} vs 21%, OR 0.4 (0.3 – 0.6), P_c0.0001], DR15 [RA_{9%} vs 15%, OR 0.5 (0.4 – 0.8), P_c0.04]. Among patients with early arthritis, being heterozygote or homozygote for DR-4 allele could not differentiate between patients with RA and UA. On the other hand, patients with UA showed higher frequency of DR7, DR11 and DR15 than RA (23%, 21%, 17% vs 13%, 11% 9%, respectively), but did not reach statistical significance after adjustment for multiple comparisons. Stepwise regression indicated that the presence of DR15 was significantly associated with lower risk of RA [OR_{0.35} (0.12–0.97, p_{0.04}].

Conclusion: In our cohort of patients with early arthritis, the genotyping of HLA-DR alleles was not useful to discriminate between RA and UA. Only the presence of DR15 allele was associated with a lower probability of RA, however the poor precision of the estimates makes it difficult to address the utility of this determination in daily clinical practice.